Class action securities litigation settlement receives final court approval

Carisma Therapeutics Inc.

U.S. District Court for Southern District of New York granted final approval on January 31, 2023.
Settlement resolves consolidated shareholder class action In re Sesen Bio, Inc. Securities Litigation.
Derivative litigation previously received final approval by Massachusetts court on November 9, 2022.
Settlement terms were previously disclosed in August 2022 Form 8-K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.